Andrew Creed, MD
Neurology · Kansas City, KSNPI 1750878013
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $15,927 with a category attached, or 62.8%. Boston Scientific accounts for 71.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $12,410 and has fallen 99.2% since, to $103 in 2025.
Across 53 payments — averaging $300.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- Abbott$2K
- Medtronic$2K
- Amneal Pharmaceuticals LLC$113
- Teva Pharmaceuticals USA, Inc.$37
- Acadia Pharmaceuticals Inc$31
- plus $28 from 1 others
What the payments were for
- Grants$10,00063%
- Travel & lodging$4,57929%
- Food & beverage$1,3498%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $11,364 |
| Abbott | 14 | $2,347 |
| Medtronic | 23 | $2,007 |
| Amneal Pharmaceuticals LLC | 3 | $113 |
| Teva Pharmaceuticals USA, Inc. | 1 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| AbbVie | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$11,279
- INFINITY$1,672
- PERCEPT PC BRAINSENSE$1,406
- PROCLAIM$480
How this compares
$15,927 in reported general payments places this provider in the 85th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 20 | $25,297 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 370 | $11,128 |
| NeuproRotigotine | 11 | $9,449 |
| Rivastigmine | 14 | $4,042 |
| Selegiline Hcl | 27 | $2,181 |
| Primidone | 45 | $1,690 |
| Gabapentin | 29 | $590 |
| AmantadineAmantadine Hcl | 13 | $510 |
| Propranolol Hcl | 23 | $474 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $348 |
| Baclofen | 32 | $328 |
| Clonazepam | 21 | $196 |
| Levetiracetam | 12 | $147 |
| Trihexyphenidyl Hcl | 15 | $116 |
| Trazodone Hcl | 19 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $113 | $25,29720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 131 neurology providers in Kansas.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- James AppelbaumKansas City$15K
- Patrick LandazuriKansas City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.